Common Side Effects During Long-Term Use
Wegovy (semaglutide) causes gastrointestinal issues in most patients, which often persist or recur with ongoing use for weight maintenance. These include nausea (up to 44% of users), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). Symptoms typically peak early but can continue, affecting adherence in long-term therapy.[1][2]
Serious Risks with Prolonged Exposure
Long-term use raises concerns for gallbladder disease (e.g., cholelithiasis in 1.6-4%), including gallstones or inflammation needing surgery. Pancreatitis occurs in about 0.2%, with symptoms like severe abdominal pain. Kidney issues, including acute injury, affect 1-2%, often tied to dehydration from GI effects. Thyroid C-cell tumors appear in rodent studies, prompting a boxed warning, though human risk remains unclear.[1][3]
Cardiovascular and Other Long-Term Effects
In trials like SELECT, extended use showed cardiovascular benefits (reduced events by 20%) but no mitigation of muscle loss or bone density declines seen with rapid weight reduction. Hypoglycemia risk increases if combined with insulin or sulfonylureas. Rare reports include vision changes (diabetic retinopathy worsening) and allergic reactions.[2][4]
What Happens If Side Effects Persist?
Persistent GI symptoms lead 7-16% to discontinue. Dose escalation (starting 0.25mg weekly, up to 2.4mg) reduces severity for some, but monitoring for dehydration, electrolyte imbalance, or suicidal thoughts (reported post-approval) is advised. No unique long-term effects beyond those in obesity trials up to 2+ years.[1][5]
Patient Experiences and Management
Users report fatigue, hair loss, and "Ozempic face" (facial sagging from fat loss) during maintenance. Strategies include anti-nausea meds, hydration, and slower titration. Consult providers for BMI-specific risks; effects may lessen after 68 weeks but not fully resolve.[3][6]
[1] Wegovy Prescribing Information, Novo Nordisk (FDA-approved label, 2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[2] STEP Trials (NEJM, 2021-2023). https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3] SELECT Trial (NEJM, 2023). https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
[4] FDA Adverse Event Reporting System (FAERS) summaries. https://www.fda.gov/drugs/questions-and-answers-fda-regarding-wegovy-semaglutide-weight-loss-and-thyroid-cancer
[5] Novo Nordisk Safety Profile. https://www.wegovy.com/taking-wegovy/side-effects.html
[6] Post-Marketing Studies and Patient Registries (JAMA, 2024). https://jamanetwork.com/journals/jama/fullarticle/2812936